![]() |
|
|
Vol. 30, Issue 3, 270-275, March 2002
Department of Drug Disposition (M.B.F., D.J., S.A.W., A.G.B.) and Pharmaceutical and Analytical Development Division (A.K.), Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
| |
Abstract |
|---|
|
|
|---|
The microsomal metabolism of 7-ethoxycoumarin (7-EC) was investigated using liquid chromatography (LC)-NMR and liquid chromatography-mass spectrometry (LC-MS) to characterize the coupling of oxidative-conjugative metabolism events. Within microsomes, cytochromes P450 (P450s) and UDP-glucuronosyltransferases (UGTs) are spatially disparate, each having surface and luminal localization, respectively. To optimize cofactor and substrate transit to UGT without compromising P450 activity, the pore-forming peptide alamethicin was used for microsomal perforation. Aqueous extracts of microsomal incubations containing NADPH and UDP-glucuronic acid were injected for LC-NMR and LC-MS analysis. The analytical complementarity of LC-NMR and LC-MS permitted the identification of four metabolites (M1 to M4). The metabolites M1 and M2 are novel microsomal metabolites for 7-EC, consistent with 3-hydroxylation and subsequent glucuronidation, respectively. Metabolites M3 and M4 were 7-hydroxycoumarin (7-HC) and 7-HC glucuronide, respectively. Viewed collectively, these results illustrate the utility of alamethicin in the examination of coupled oxidative-conjugative metabolism and the synergy of LC-NMR and LC-MS in metabolite identification.
| |
Introduction |
|---|
|
|
|---|
The
cytochrome P450 (P4502) superfamily of enzymes is
encoded by more than 40 genes in humans (Nelson et al., 1996
), and at least 12 members in the first three families (CYP1-3) are involved in
xenobiotic metabolism and drug-drug interactions (Wrighton and Stevens,
1992
). As the biochemistry and enzymology of this enzyme system have
evolved and all of the human xenobiotic-metabolizing isoforms have been
cloned and expressed, selective substrates have been identified that
will yield information about catalytic activity of a specific form when
present in a crude mixture (Hickman et al., 1998
). Indeed, specific
probes have been used in systems such as human liver microsomes, liver
slices (VandenBranden et al., 1998
), hepatocytes (Li, 2001
), and in
vivo (Streetman et al., 2000
). For example, specific metabolite
formation from warfarin and testosterone and metabolism of various
alkoxyresorufins have been used as in vitro probes for various P450
forms (Rettie et al., 1995
). The enzymology of other drug-metabolizing
enzyme systems, such as the UDP-glucuronosyltransferases (UGTs) and
sulfotransferases, has not been as well characterized to date, and thus
in many cases, a nonspecific or generic substrate has been used
(VandenBranden et al., 1998
; Hashemi et al., 1999
).
7-Ethoxycoumarin (7-EC) is one of the most commonly used in vitro
metabolic probes to date. It has been used in hepatocytes and liver
slices for in vitro predictions of in vivo hepatic clearance (Carlile
et al., 1999
), as a positive control for metabolic lability of in vitro
systems (VandenBranden et al., 1998
; Hashemi et al., 1999
), and in
addition as a probe substrate for specific P450s (Yamazaki et al.,
1996
; Shimada et al., 1999
). Oxidative deethylation of 7-EC by
CYP1A2 (low-Km component) and by
CYP2E1 and 2B6 (high-Km components)
(Yamazaki et al., 1996
) generates 7-hydroxycoumarin (7-HC;
umbelliferone), which is then susceptible to conjugation by as yet
uncharacterized UGT forms when present with the appropriate cofactor.
Although sequential metabolism of 7-EC to 7-HC glucuronide has been
routinely observed in hepatocytes and liver slices, minimal examination
of its coupled oxidation-glucuronidation has been examined in
microsomes (Matsubara et al., 1982
). This is primarily due to the
differential localization of the UGT and P450 enzyme systems on the
lumen and surface of the microsomal membrane, respectively. The
microsomal membrane imparts a diffusional barrier to the luminal UGT
enzyme, and specialized treatments, typically detergents, facilitate
cofactor, substrate, and product diffusion but often inhibit P450
activity. The pore-forming peptide alamethicin has recently been
applied to microsomal glucuronidation and been shown not to attenuate
P450 activity, thus providing a practical means for accessing
metabolite generation via sequential oxidation-glucuronidation reactions (Fisher et al., 2000
).
The current studies were undertaken to characterize the
oxidative-conjugative microsomal metabolites of 7-EC with LC-NMR. LC-NMR, the hyphenation of chromatographic separation with magnetic resonance structural characterization, dates back to the 1970s (Bayer
et al., 1979
). However, this methodology has only recently come of age,
as articles attest to growing application in the field of drug
metabolism (Lindon et al., 1996
, 1997
). Most recently, challenging
regiochemistry problems related to acetylenic metabolism (Mutlib et
al., 1999
, 2000
), NIH shift metabolites (Dear et al., 2000
), and
quinoline oxidation/glucuronidation (Ehlhardt et al., 1998
) have been
deciphered with LC-NMR. This article reports the application of LC-NMR
and LC-MS for the characterization of two sets of coupled phase I and
phase II metabolites formed from human liver microsomes perforated with
alamethicin and supplemented with the substrate 7-EC and the cofactors
NADPH and UDP-glucuronic acid (UDPGA), respectively.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals. UDPGA, saccharic acid-1,4-lactone, alamethicin, trifluoroacetic acid, 7-EC, 7-HC, and coumarin were purchased from Sigma Chemical Co. (St. Louis, MO). HPLC-grade acetonitrile was obtained from Burdick and Jackson (Muskegon, MI). 7-Hydroxycoumarin glucuronide and 7-hydroxycoumarin sulfate were obtained from GENTEST (Woburn, MA) or Salford Ultrafine Chemicals and Research (Manchester, UK). D2O (99.9% D) and CD3CN (96-97% D) were obtained from Cambridge Isotopes Laboratories (Cambridge, MA).
Liver Specimens.
Human liver specimens were obtained, and microsomes were prepared as
described previously (Fisher et al., 2000
). Microsomes from a mixture
of nine human livers (HL samples A, B, C, D, F, G, H, L, and M) were
used for all studies.
Ethoxycoumarin Metabolism.
For microsomal metabolism of 7-EC, 0.1 to 0.3 mg of human liver
microsomes, 0.1 M sodium phosphate buffer, pH 7.4, 50 µg of alamethicin/mg of microsomal protein, 1 mM MgCl2,
5 mM saccharic acid-1,4-lactone, and 250 µM 7-EC were incubated with
1 mM NADPH, with and without 5 mM UDPGA, in a final volume of 200 µl
for 15 to 45 min. Reactions were stopped by the addition of 50 µl of 5% (v/v) HCl and 20 µl of 0.2 mM coumarin as internal standard. Blank incubations were performed without cofactor, and cofactor was
added after quenching the incubation. Samples were centrifuged to
pellet-precipitated material, and 25 to 30 µl was injected for HPLC
analysis. Analysis was performed on a Shimadzu (Kyoto, Japan) HPLC
system, equipped with two LC-10AD pumps, an SCL-10A system controller,
an SIL-10A autoinjector, an SPD-10A UV/Visible detector set to 320 nm,
and a 3-µm C18(3) Luna 100 × 4.6 column (Phenomenex, Torrance, CA). In some chromatographic runs, a Shimadzu RF-10A fluorescence detector set to excitation and emission wavelengths of 323 and 463 nm, respectively, was used to detect analytes. The
mobile phase was 0.05% trifluoroacetic acid in water (solvent A) and
0.05% trifluoroacetic acid in acetonitrile (solvent B). Initial
conditions were 88% solvent A and 12% solvent B. Analytes were eluted
with a linear gradient to 65% solvent B over 12.5 min. Metabolite
formation was quantitated by comparing peak area ratios
(metabolite/internal standard) in incubations with ratios obtained from
a standard curve containing known amounts of 7-HC (M3) and 7-HC
glucuronide (M4). Standard curve correlation coefficients (r2) were
0.99. Quantities of the
unknown metabolites M1 and M2 were estimated using standard curves for
M3 and M4, respectively. Incubations for LC-NMR analysis were performed
as described above; however these incubations were stopped with an
equal volume of cold acetonitrile, lyophilized overnight, reconstituted
in mobile phase (90% solvent A/10% solvent B), and centrifuged to
remove insoluble material.
= 320 nm) detector. The LC-NMR system was operated in stop-flow mode
using Varian Cascade software. After detection of an analyte apex, a
13.5-s delay allowed transit of the analyte to the flow cell in the
probe. The field frequency was locked on the 2H
resonance of CD3CN, and spectra were referenced
to the residual proton resonance of CD3CN (2.00 ppm). Suppression of resonances from HOD and the
CHD2CN resonance was accomplished using the water elimination through transverse gradients (WET) technique (Ogg et al.,
1994
B2) of
approximately 250 Hz. HPLC conditions were identical to those described
above, except solvent A and solvent B were prepared with deuterium
oxide and deuterated acetonitrile, respectively.
| |
Results and Discussion |
|---|
|
|
|---|
In earlier studies on the oxidation/conjugation of 7-EC in
microsomes, alamethicin was applied using 50 µg/mg of microsomal protein (Fisher et al., 2000
). When supplemented with NADPH as the sole
cofactor, 7-EC was formed without impairment of P450 function, whereas
in the presence of both NADPH and UDPGA as cofactors sequential
dealkylation and glucuronidation occurred. Characterization of the
product profile by HPLC-UV allowed not only the known products 7-HC
(M3) and 7-HC glucuronide (M4) [at retention times
(tR) of 7.9 and 4.0 min,
respectively] to be quantitated (Table
1) but also unearthed two unexpected
microsomal metabolites, M1 and M2 (tR
at 12.0 and 8.9 min, respectively) (Table 1).
|
The HPLC-UV and HPLC-fluorescence properties of M1 and M2 suggested that they were metabolites related to 7-EC. All four metabolites were fluorescent, although M1 and M4 were minor peaks with this detection method. When quantities of M1 and M2 were estimated by HPLC-UV using standard curves for 7-HC and 7-HC glucuronide, respectively, they appeared to be similar in abundance to the known metabolites (Table 1). LC-MS data supported M1 and M2 being the result of sequential hydroxylation and glucuronidation. M+H+ ions of M1 and M2 at m/z 207 and 383, respectively, were 16 amu (hydroxylation) and 192 amu (hydroxylation/glucuronidation) higher than that of the parent drug. By comparison, the M+H+ for M3 (M+H+ at m/z 163) and M4 (M+H+ at m/z 339) were consistent with metabolites formed by sequential oxidative deethylation and glucuronidation, respectively. Additionally, the LC-MS source-induced loss of 176 amu from the putative glucuronide M2 afforded a fragment consistent with M+H+ of the corresponding aglycone M1. Collision-induced dissociation of the M+H+ of M2 led to a very facile loss of 176 amu, whereas collision-induced dissociation of the M+H+ of M1 yielded loss of CO as the only discernible fragment. Unfortunately, LC-tandem mass spectrometry gave no information on molecular connectivity. Taken together, these data suggest that M1 arises through hydroxylation of 7-EC without dealkylation, and M2 arises via glucuronidation of M1. However, ascertaining the regiochemistry of these biotransformations necessitated LC-NMR (Table 2).
|
Microsomal incubations for analysis by HPLC-NMR were supplemented with
NADPH alone (M1 and M3 only metabolites) or NADPH and UDPGA (M2 and M4
major metabolites). As illustrated in Fig.
1, the NMR spectrum of M1 shows the
absence of the resonance for H3 and the collapse of the H4 doublet to a
singlet compared with the parent, 7-EC (Fig. 1). Furthermore, relative
to the parent, there is an up-field shift in the H4 resonance (
0.78
ppm) and, to a lesser extent, the H5 resonance
0.13 ppm). There is
little change in the chemical shifts of H6 and H8. Interpreted in
conjunction with LC-MS data, the NMR properties of M1 indicate a
3-hydroxy substituent on 7-EC.
|
The NMR spectrum of M2 (Fig. 1) supported glucuronidation at position
3, with the absence of resonance at 6.30 ppm (compared with parent
compound) and the presence of resonances at 3.3 to 4.2 ppm,
attributable to protons H2' to H5'. Of the resonances that were
retained in M2 compared with the parent, the change in H4 was the most
pronounced, its up-field shift (
0.39 ppm) considered attributable to
the shielding glucuronide ether. Another diagnostic feature of M2 was
the isolated resonance ascribed to H6', which, occurring at 5.10 ppm,
was characteristic for the anomeric proton of glucuronides (Kaspersen
and Van Boeckel, 1987
). Homonuclear decoupling experiments yielded
further support to position-3 substitution by verifying
J-coupling between the chemical shifts at 7.52 and 6.99 ppm
(Fig. 2). Saturation of the resonance in
the region of 6.99 ppm resulted in the collapse of the doublet at 7.54 ppm to a singlet. This collapsed singlet was assigned to H5, and the
other singlet at 7.52 ppm was assigned to H4. Furthermore, in the
converse experiment (data not shown), saturation of the resonance at
7.52 to 7.54 ppm deconvoluted the partially overlapping peaks at 6.98 to 6.99 ppm into the apparent single coincident resonance assigned to
H6 and H8.
|
The metabolites M3 and M4, identified by LC-MS as the O-dealkylated and phenolic glucuronide, respectively (vide supra), were characterized by the loss of resonances H9 and H10 (Fig. 3). Furthermore, the up-field shift of H6 and H8 for M3 (0.05 and 0.1 ppm relative to the parent, respectively) can be attributed to the stronger shielding of the unmasked phenol in M3 compared with the parent ether. The resonance for H6 of M3 occurred as a doublet of doublets (J5,6 = 8.6 Hz; J6,8 = 2.3 Hz) and H8 as a doublet (J8,6 = 2.3 Hz). Similar coupling constants were observed for M4, as was the loss of resonances for H9 and H10. Typical glucuronide resonances were observed also (H2'-H6'). These data support M4 as a glucuronide attached via the ether linkage at position 7. Interestingly, the anomeric proton resonance (H6') of M4 occurred as two overlapped doublets. This may be attributed to some conformational averaging of two states that is slow on the NMR timescale rather than additional J-coupling (H6' is only J-coupled to H5'). It is not known why this is observed for M3 compared with M1, and further experiments are required to investigate this phenomenon.
|
The formation of M1 and M2 from 7-EC was unexpected and clearly
illustrative of the coupled oxidation-glucuronidation activity of
alamethicin-treated microsomes. The proposed pathway for the formation
of these four metabolites is shown in Fig.
4. During the course of P450 catalysis,
the heme-bound intermediate proceeding from olefin
-electron
abstraction from 7-EC could conceivably give rise to either an epoxide
or a ketone (Liebler and Guengerich, 1983
) that tautomerizes to the
more stable allylic alcohol. It is noteworthy that in the P450-mediated
oxidation of coumarin, the 3,4-epoxide is not an intermediate in the
formation of 3-hydroxycoumarin (Born et al., 1997
). Interestingly,
incubation of 250 µM 7-EC with cryopreserved human hepatocytes,
thawed and in suspension, generated significant quantities of
7-hydroxycoumarin glucuronide (data not shown). However, no evidence
for 3-hydroxy-derived metabolites was observed. It is clear that
significant differences exist between coupled oxidation-glucuronidation
in microsomes and hepatocytes for 7-EC, and further studies are
necessary to elucidate these differences.
|
In the work presented here, LC-NMR was applied to the characterization
of 7-HC (M3) and 7-HC glucuronide (M4), previously reported as
metabolites of 7-EC in alamethicin-treated microsomes (Fisher et al.,
2000
). More importantly, however, LC-NMR proved to be a powerful tool
in the structural elucidation of metabolites M1 and M2 derived from a
novel 3-hydroxylation pathway in human microsomes. In fact, metabolites
from the latter pathway were apparently as abundant as those formed
from dealkylation as judged by HPLC-UV. Metabolites from
7-alkoxycoumarins that proceed via routes other than dealkylation have
been observed previously. The metabolism of 7-butoxycoumarin has been
shown to proceed predominantly through 3- and 4-hydroxylation pathways,
although this was performed with rat CYP2B1 and these alternative
metabolites were not seen with 7-EC (Kobayashi et al., 1998
). Also,
6-hydroxylation of 7-EC by rat liver P450 has been reported, occurring
as a consequence of metabolic switching upon deuteration of the
ethoxymethylene of 7-EC (Harada et al., 1984
). Alternative unidentified
metabolites have been observed after incubation of 7-EC with rat liver
slices (Ball et al., 1996
), and apparent lactone ring oxidation was
observed in guinea pig and dog liver slices (Terada et al., 1996
).
However, to our knowledge neither 3-hydroxy nor 3-hydroxyglucuronide
formation from 7-EC has been previously reported from human liver microsomes.
The formation of these alternative metabolites could add complexity to
data derived from 7-EC metabolism generated with microsomes. Indeed,
rapid HPLC analysis of 7-EC incubations could obscure retention time
differences and thus confound metabolite determinations. Additionally,
as some assays of 7-EC biotransformation (Ball et al., 1996
; Hashemi et
al., 1999
) may use total fluorescence with and without
-glucuronidase treatment to quantitate metabolism, the observed
fluorescence of the 3-hydroxyglucuronide could distort experimental
conclusions. Also, since 7-EC can be used as an in vitro probe for
CYP1A1 or 1A2 at low concentrations (Yamazaki et al., 1996
) and the
enzymology of 7-EC 3-hydroxylation has not yet been evaluated, care
must be taken to ensure unambiguous metabolism data depending upon the
analytical method used.
| |
Acknowledgments |
|---|
We thank Anne Pak for performing the hepatocyte incubation and Cliff Fisher for many helpful discussions.
| |
Footnotes |
|---|
Received September 14, 2001; accepted December 6, 2001.
1 Current address: Discovery Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Pfizer, Inc., Groton, CT 06340.
Dr. Anthony G. Borel, Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285. E-mail: borel_anthony_g{at}lilly.com
| |
Abbreviations |
|---|
Abbreviations used are: P450, cytochrome P450; UGT, UDP-glucuronosyltransferases; 7-EC, 7-ethoxycoumarin; 7-HC, 7-hydroxycoumarin; LC, liquid chromatography; MS, mass spectrometry; UDPGA, UDP-glucuronic acid; HPLC, high-performance liquid chromatography; amu, atomic mass unit.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C.-H. Yun, K.-H. Kim, M. W. Calcutt, and F. P. Guengerich Kinetic Analysis of Oxidation of Coumarins by Human Cytochrome P450 2A6 J. Biol. Chem., April 1, 2005; 280(13): 12279 - 12291. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||